Related Experiment Video

Updated: Aug 17, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future

Nicola Normanno1, Antonella De Luca, Monica R Maiello

  • 1Cell Biology and Preclinical Models, INT-Fondazione Pascale, 80131 Naples, Italy. nicnorm@yahoo.com

Frontiers in Bioscience : a Journal and Virtual Library
|June 23, 2005
PubMed

Insights

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors show limited efficacy as single agents in breast cancer. Combination therapies targeting multiple pathways may be crucial for advanced disease and specific patient subgroups.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) and its ligands play a role in human carcinoma pathogenesis, including breast cancer.
  • Phase II trials indicate limited single-agent activity of EGFR tyrosine kinase inhibitors (TKIs) in breast cancer patients.

Purpose of the Study:

  • To discuss potential pitfalls in clinical trials of EGFR TKIs for breast cancer.
  • To explore molecular mechanisms of breast cancer cell sensitivity/resistance to EGFR TKIs.
  • To review potential therapeutic strategies involving EGFR TKIs.

Main Methods:

  • Review of preclinical findings on breast cancer cell resistance mechanisms to EGFR-targeted therapies.
  • Analysis of clinical trial data regarding EGFR TKI efficacy.
  • Discussion of molecular pathways involved in growth factor-driven signaling.

Main Results:

  • Breast cancer cells employ diverse mechanisms to evade anti-tumor effects of EGFR-targeted drugs.
  • Combined blockade of multiple growth-promoting pathways may be necessary for significant tumor growth inhibition, especially in advanced stages.
  • EGFR TKIs show promise in specific subgroups, such as estrogen receptor-positive (ER+), tamoxifen-resistant breast cancer patients.

Conclusions:

  • Preclinical data suggest breast cancer cells can develop resistance to EGFR TKIs through various molecular mechanisms.
  • Combined therapeutic strategies blocking multiple growth pathways are likely required for effective treatment of advanced breast cancer.
  • EGFR TKIs may be beneficial for specific patient populations, such as ER+, tamoxifen-resistant breast cancer, and could be explored in combination therapies.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...